Evaluation of Safety of Treatment With Anti–Epidermal Growth Factor Receptor Antibody Drug Conjugate MRG003 in Patients With Advanced Solid Tumors: A Phase 1 Nonrandomized Clinical Trial

IMPORTANCE: The antibody drug conjugate drug MRG003 comprises an anti–epidermal growth factor receptor (EGFR) humanized immunoglobulin G1 monoclonal antibody that is conjugated with monomethyl auristatin E via a valine-citrulline linker. There is currently insufficient evidence of this drug's s...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiu, Miao-Zhen, Zhang, Yang, Guo, Ye, Guo, Wei, Nian, Weiqi, Liao, Wangjun, Xu, Zhongyuan, Zhang, Wenxue, Zhao, Hong-Yun, Wei, Xiaoli, Xue, Liqiong, Tang, Wenbo, Wu, Yunteng, Ren, Guoxin, Wang, Ling, Xi, Jingle, Jin, Yongshuai, Li, Hu, Hu, Chaohong, Xu, Rui-Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9073657/
https://www.ncbi.nlm.nih.gov/pubmed/35511148
http://dx.doi.org/10.1001/jamaoncol.2022.0503

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9073657/
https://www.ncbi.nlm.nih.gov/pubmed/35511148
http://dx.doi.org/10.1001/jamaoncol.2022.0503

Ejemplares similares